P39 Real world experience of using bezafibrate for PBC
P39 Real world experience of using bezafibrate for PBC
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
Primary Biliary Cholangitis (PBC) is a rare autoimmune condition with an incidence of 20–40 cases per 100,000. Levels of alkaline phosphatase (ALP) can be used as a surrogate marker of clinical response to pharmacotherapy. Ursodeoxycholic acid (UDCA) is first line therapy and Obeticholic acid (OCA) is second line therapy for those intolerant or unr...
Alternative Titles
Full title
P39 Real world experience of using bezafibrate for PBC
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2446893809
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2446893809
Other Identifiers
ISSN
0017-5749
E-ISSN
1468-3288
DOI
10.1136/gutjnl-2020-BASL.49
